# K152614: Xpert Carba-R

- Pathway: 510(k) (Traditional)
- Applicant: Cepheid
- Decided: Mar 7, 2016 after 175 days
- Product code: PMY (System, Nucleic Acid Amplification Test, Dna, Carbapenem Non-Susceptible Gram Negative Organism, Colony)
- Device class: 2
- Regulation: 21 CFR 866.1640
- Recalls of this device: none
- Data: FDA decisions to Oct 25, 2026; recalls to Oct 12, 2026

## Lineage
Longest line of descent: 3 generations back to K972359 (1997). 3 ancestors in all.
6 later devices descend from it; 3 cite it directly.
0 of 10 devices in its family (counting itself) have a Class I recall.

## Predicates on the family tree (from the FDA summary)
- K092953: Xpert VanA Assay, Cepheid (2009) Summary page 4.

## Most influential descendants
- K160901: Xpert Carba-R (2016), 3 descendants of its own
- K173263: Xpert Carba-R (2018), 1 descendant of its own
- K261867: Xpert Carba-R (2026), 0 descendants of its own
- K191288: Acuitas AMR Gene Panel (2021), 0 descendants of its own
- K190613: BD MAX Check-Points CPO (2019), 0 descendants of its own

## Indications for use
The Xpert® Carba-R Assay, performed on the GeneXpert® Instrument Systems, is a qualitative in vitro diagnostic test for the detection and differentiation of the blaKPC, blaNDM, blaVIM, blaOXA-48, and blaIMP gene sequences associated with carbapenem-non-susceptible pure colonies of Enterobacteriaceae, Acinetobacter baumannii, or Pseudomonas aeruginosa grown on blood agar or MacConkey agar. The test utilizes automated real-time polymerase chain reaction (PCR). A negative Xpert Carba-R Assay result does not preclude the presence of other resistance mechanisms. The Xpert Carba-R Assay should be used in conjunction with other laboratory tests including phenotypic antimicrobial susceptibility testing. The Xpert Carba-R Assay is intended as an aid for infection control in detecting and differentiating genetic markers of resistance to monitor the spread of carbapenem-non-susceptible organisms in healthcare settings. The Xpert Carba-R Assay is not intended to guide or monitor treatment for carbapenem-non-susceptible bacterial infections.

Source page: https://510kreport.com/device/K152614
Methodology: https://510kreport.com/methodology